Servicio de Nefrología, Hospital Universitario Dr. Peset, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Fisabio), Valencia, España.
Servicio de Nefrología, Hospital Universitario Dr. Peset, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Fisabio), Valencia, España.
Nefrologia (Engl Ed). 2021 Mar-Apr;41(2):200-209. doi: 10.1016/j.nefro.2020.12.007. Epub 2021 Feb 13.
The number of patients who start dialysis due to graft failure increases every day. The best dialysis modality for this type of patient is not well defined and most patients are referred to HD. The objective of our study is to evaluate the impact of the dialysis modality on morbidity and mortality in transplant patients who start dialysis after graft failure.
A multicentre retrospective observation and cohort study was performed to compare the evolution of patients who started dialysis after graft failure from January 2000 to December 2013. One group started on PD and the other on HD. The patients were followed until the change of dialysis technique, retransplantation or death. Anthropometric data, comorbidity, estimated glomerular filtration rate (eGFR) at start of dialysis, the presence of an optimal access for dialysis, the appearance of graft intolerance and retransplantation were analysed. We studied the causes for the first 10 hospital admissions after starting dialysis. For the statistical analysis, the presence of competitive events that hindered the observation of the event of interest, death or hospital admission was analysed.
175 patients were included, 86 in DP and 89 in HD. The patients who started PD were younger, had less comorbidity and started dialysis with lower eGFR than those on HD. The mean follow-up was 34 ± 33 months, with a median of 24 months (IQR 7 - 50 months), Patients on HD had longer follow-up than patients on PD (35 vs. 18 months, p = < 0.001). The mortality risk factors were age sHR 1.06 (95% CI: 1.033 - 1.106, p = 0.000), non-optimal use of access for dialysis sHR 3.00 (95% CI: 1.507 - 5.982, p = 0.028) and the dialysis modality sHR (PD / HD) 0.36 (95% CI: 0.148 - 0.890, p = 0.028). Patients on PD had a lower risk of hospital admission sHR [DP / HD] 0.52 (95% CI: 0.369-0.743, p = < 0.001) and less probability of developing graft intolerance HR 0.307 (95% CI 0.142-0.758, p = 0.009).
With the limitations of a retrospective and non-randomized study, it is the first time nationwide that PD shows in terms of survival to be better than HD during the first year and a half after the kidney graft failure. The presence of a non-optimal access for dialysis was an independent and modifiable risk factor for mortality. Early referral of patients to advanced chronic kidney disease units is essential for the patient to choose the technique that best suits their circumstances and to prepare an optimal access for the start of dialysis.
由于移植物失功而开始透析的患者人数每天都在增加。对于这类患者,最佳的透析方式尚未明确,大多数患者被转介到血液透析(HD)。我们的研究目的是评估移植物失功后开始透析的患者的透析方式对发病率和死亡率的影响。
进行了一项多中心回顾性观察性队列研究,比较了 2000 年 1 月至 2013 年 12 月期间因移植物失功而开始透析的患者的演变情况。一组开始接受 PD 治疗,另一组开始接受 HD 治疗。患者随访至透析技术改变、再次移植或死亡。分析了患者的人体测量数据、合并症、透析开始时的估算肾小球滤过率(eGFR)、透析的最佳通路情况、移植物不耐受的出现以及再次移植的情况。我们研究了开始透析后的前 10 次住院的原因。对于统计分析,分析了存在竞争事件(妨碍观察感兴趣事件的发生)、死亡或住院的情况。
共纳入 175 例患者,其中 86 例接受 DP 治疗,89 例接受 HD 治疗。开始 PD 治疗的患者更年轻,合并症更少,开始透析时的 eGFR 也低于 HD 治疗的患者。平均随访时间为 34±33 个月,中位数为 24 个月(IQR 7-50 个月)。HD 治疗的患者随访时间长于 PD 治疗的患者(35 个月比 18 个月,p<0.001)。死亡的危险因素包括年龄(sHR 1.06,95%CI:1.033-1.106,p=0.000)、透析通路非最佳利用(sHR 3.00,95%CI:1.507-5.982,p=0.028)和透析方式(sHR(PD/HD)0.36,95%CI:0.148-0.890,p=0.028)。PD 治疗的患者住院风险较低(sHR [DP/HD] 0.52,95%CI:0.369-0.743,p<0.001),发生移植物不耐受的概率也较低(HR 0.307,95%CI 0.142-0.758,p=0.009)。
在回顾性和非随机研究的限制下,这是首次在全国范围内表明,PD 在移植物失功后 1 年半内的生存方面优于 HD。透析通路非最佳利用是死亡的独立和可改变的危险因素。早期将患者转至慢性肾脏病高级治疗单位对于患者选择最适合其情况的技术以及为开始透析做好最佳通路准备至关重要。